These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk. Lacroix P; Crumb WJ; Durando L; Ciottoli GB Eur J Pharmacol; 2003 Sep; 477(1):69-72. PubMed ID: 14512100 [TBL] [Abstract][Full Text] [Related]
3. Does the prulifloxacin ECG study prove cardiac safety of the drug? Malik M Clin Drug Investig; 2010; 30(1):1-3. PubMed ID: 19995093 [No Abstract] [Full Text] [Related]
4. Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans. Maraki S; Lionakis S; Ntaoukakis M; Barbounakis E; Ntasis E; Kofteridis DP; Samonis G Med Mycol; 2011 May; 49(4):419-23. PubMed ID: 21108571 [TBL] [Abstract][Full Text] [Related]
5. Effects of prulifloxacin on cardiac repolarization in healthy subjects: a randomized, crossover, double-blind versus placebo, moxifloxacin-controlled study. Rosignoli MT; Di Loreto G; Dionisio P Clin Drug Investig; 2010; 30(1):5-14. PubMed ID: 19995094 [TBL] [Abstract][Full Text] [Related]
6. Prulifloxacin as a trigger of myasthenia gravis. Rossi M; Lusini G; Biasella A; Mazzocchio R J Neurol Sci; 2009 May; 280(1-2):109-10. PubMed ID: 19232642 [TBL] [Abstract][Full Text] [Related]
7. Acute renal failure probably induced by prulifloxacin in an elderly woman : a first case report. Gallelli L; Gallelli A; Vero G; Roccia F; Pelaia G; De Sarro G; Maselli R Clin Drug Investig; 2006; 26(1):49-53. PubMed ID: 17163235 [No Abstract] [Full Text] [Related]
9. Liver injury in the elderly due to fluoroquinolones: should these drugs be avoided? Hayashi PH; Chalasani NP CMAJ; 2012 Oct; 184(14):1555-6. PubMed ID: 22891207 [No Abstract] [Full Text] [Related]
10. Intravenous moxifloxacin. Even more harmful than the oral form. Prescrire Int; 2011 Jun; 20(117):151. PubMed ID: 21678703 [No Abstract] [Full Text] [Related]
11. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. Price MO; Price FW; Maclellan D J Cataract Refract Surg; 2005 Nov; 31(11):2137-41. PubMed ID: 16412928 [TBL] [Abstract][Full Text] [Related]
12. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa. Roveta S; Schito AM; Marchese A; Schito GC Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467 [TBL] [Abstract][Full Text] [Related]
13. Moxifloxacin: new indication. Do not use in gynaecological infections or other conditions. Prescrire Int; 2009 Oct; 18(103):207. PubMed ID: 19882788 [TBL] [Abstract][Full Text] [Related]
14. Moxifloxacin and torsade de pointes. Dale KM; Lertsburapa K; Kluger J; White CM Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508 [TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Peloquin CA; Hadad DJ; Molino LP; Palaci M; Boom WH; Dietze R; Johnson JL Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980 [TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. Prescrire Int; 2009 Oct; 18(103):206. PubMed ID: 19882787 [TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Andriole VT; Haverstock DC; Choudhri SH Drug Saf; 2005; 28(5):443-52. PubMed ID: 15853445 [TBL] [Abstract][Full Text] [Related]